Restoril Generic Name & Formulations
Mechanism of Action
Restoril Dosage and Administration
Restoril Boxed Warnings
Increased risk of drug-related mortality from concomitant use with opioids. Risk of CNS depressant effects and next-day impairment. Evaluate for co-morbid diagnoses before initiation. Reevaluate if insomnia fails to remit after 7–10 days of use. Depression. Suicidal tendencies. Abnormal thinking and behavioral changes. Chronic pulmonary insufficiency. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Drug or alcohol abusers. Write ℞ for smallest practical amount. Renal or hepatic impairment. Elderly (higher risk of falls). Debilitated. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: monitor infants.
96% plasma protein bound.
Renal (80–90%). Half-life: 3.5–18.4 hours.
Restoril Adverse Reactions
Restoril Clinical Trials
Restoril Patient Counseling